Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phage therapy for decolonization of KPC-producing Klebsiella pneumoniae in high-risk adults
RBR-9f3whw9Phase 2Not yet recruiting
- Sponsor
- Federal University of São Paulo
- Start
- Sep 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in carbapenem-resistant klebsiella pneumoniae colonization, sponsored by Federal University of São Paulo. Primary endpoint: Safety and tolerability. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
carbapenem-resistant klebsiella pneumoniae colonization
Beyond the preview
Go deeper on RBR-9f3whw9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9f3whw9.